Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06397976 · ClinicalTrials.gov registry record
The Heidelberg Engineering ANTERION Software Comparison Precision and Agreement Study
A clinical trial, sponsored by Heidelberg Engineering.
- Terminated
- Registry status
- 37
- Enrollment target
NCT06397976: Clinical Trial study, sponsored by Heidelberg Engineering.
NCT06397976 is a clinical trial that was terminated before completion, run by Heidelberg Engineering. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06397976 was terminated before completion, sponsored by Heidelberg Engineering.
- TERMINATED
- Registry status
- 37 participants
- Enrollment target
Study Summary
This study is conducted to compare the the investigational device ANTERION with software version 1.5 against the ANTERION with software version 1.2.4 (cleared version)
Primary Outcome
Reproducibility and repeatability of Central Cornea Thickness of ANTERION and the reference device
Interventions
- DEVICE ANTERION investigational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2024-11-05 |
Why NCT06397976 stopped before completion
NCT06397976 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ANTERION investigational is the first listed.
NCT06397976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06397976 about?
NCT06397976 is a clinical study titled "The Heidelberg Engineering ANTERION Software Comparison Precision and Agreement Study". This study is conducted to compare the the investigational device ANTERION with software version 1.5 against the ANTERION with software version 1.2.4 (cleared version)
What is the current status of trial NCT06397976?
This trial is currently terminated. The enrollment target is 37 participants. The study started on 2024-04-17. Estimated completion is 2024-11-05.
What interventions are being tested in trial NCT06397976?
The interventions under investigation include: ANTERION investigational (DEVICE).
Who is sponsoring clinical trial NCT06397976?
This trial is sponsored by Heidelberg Engineering, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI